Current Report Filing (8-k)
February 08 2018 - 01:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
February 8, 2018
(February 7, 2018)
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS,
INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-15697
|
|
22-3542636
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
165 Ludlow Avenue, Northvale, New Jersey
07647
(Address of principal executive offices)
(201) 750-2646
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 7.01
|
Regulation FD Disclosure.
|
On February 8, 2018, in a press release,
Elite Pharmaceuticals, Inc., or Elite, reported that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and
Drug Administration for a generic version of an immediate release CNS stimulant. The
ANDA represents the first filing for a product co-developed with SunGen Pharma, LLC under the Development and License Agreement.
A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release
furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite’s filings under the Securities
Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall
be expressly set forth by specific reference in any such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
99.1
|
Press Release dated February 8, 2018
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: February 8, 2018
|
ELITE PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Nasrat Hakim
|
|
|
|
Nasrat Hakim, President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2023 to Mar 2024